Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre.
OBJECTIVE
Using pathological and clinical review, to identify all cases diagnosed as peripheral T cell and natural killer (NK) T cell lymphoma over 10 years from one metropolitan Australian hospital.


RESULTS
Subtyping was performed using World Health Organization (WHO) 2008 criteria and a comprehensive immunohistochemical panel. Clinical data including follow-up were obtained. There were 47 cases, including 11 peripheral T cell lymphomas, not otherwise specified (NOS), nine extranodal NK T cell lymphomas, nasal type (eight nasal), eight primary cutaneous anaplastic large cell lymphomas, seven angioimmunoblastic T cell lymphomas, three anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphomas, four ALK-negative anaplastic large cell lymphomas, three enteropathic T cell lymphomas and two subcutaneous panniculitis-like T cell lymphomas. Follow-up of 46 of 47 cases (median time 45 months) revealed that 50% (23 of 46) of patients died. Five-year survival rates were: peripheral T cell lymphoma, NOS 39%; angioimmunoblastic T cell, 43%; nasal NK T 67%; ALK-negative anaplastic large cell lymphoma 67% (at 2 years); ALK(+) anaplastic large cell lymphoma 33%; subcutaneous panniculitis-like T cell lymphomas 100%; primary cutaneous anaplastic large cell lymphoma 86%; and enteropathic T cell lymphoma 33% (at 1 year). One patient with Lennert lymphoma suffered four late cutaneous relapses.


CONCLUSIONS
This first Australian clinicopathological series of peripheral T cell and NK T cell lymphoma shows epidemiological and survival data similar to those for Europe and North America.
Departments of Anatomical Pathology Haematology, St Vincent's Hospital Melbourne, Victoria, Australia. penny.mckelvie@svhm.org.au
Penelope A
PA
McKelvie
Philip A
PA
Thompson
Constantine S
CS
Tam
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077548:Anaplastic Lymphoma Kinase; D001315:Australia / Q000453:epidemiology; D018572:Disease-Free Survival; D058527:Enteropathy-Associated T-Cell Lymphoma / Q000276:immunology / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D054391:Lymphoma, Extranodal NK-T-Cell / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000276:immunology / Q000401:mortality / Q000473:pathology; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000276:immunology / Q000401:mortality / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000276:immunology / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D012878:Skin Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D055815:Young Adult
C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases